Global Injectable Drug Delivery Market to Reach USD 113.87 Billion by 2034 grow at a healthy CAGR of 8.70% | FMI

The UK injectable drug delivery market is set to grow at 8.80% CAGR through 2034, driven by rising obesity rates and the approval of weight-loss injectable.

NEWARK, DE, UNITED STATES, January 23, 2025 /EINPresswire.com/ -- The healthcare industry is experiencing a transformation in drug delivery, with injectable systems gaining traction as healthcare professionals seek more effective treatments for life-threatening diseases. The global injectable drug delivery market is projected to reach USD 49.44 billion by 2024, driven by the rising adoption of telemedicine in both developed and developing regions.

This trend has fueled steady market growth, with a projected CAGR of 8.70% through 2034. Pharmaceutical companies are seizing the opportunity to develop advanced devices for managing chronic and age-related conditions. As the global prevalence of chronic diseases continues to rise, the market is expected to grow significantly, reaching an estimated USD 113.87 billion by 2034.

The demand for more convenient and efficient drug delivery solutions will remain a key driver of market expansion, urging companies to innovate and adapt to evolving patient needs.

Key Drivers Fueling Growth:

1. Rising Prevalence of Chronic Diseases:
Chronic conditions such as diabetes and rheumatoid arthritis are fueling the demand for injectable drugs, particularly biologics and biosimilars. For instance, the growing adoption of insulin pens and prefilled syringes highlights the need for user-friendly and efficient systems.

2. Technological Advancements:
Innovations such as smart injectors, wearable injectors, and connected drug delivery devices are transforming how medications are administered. These technologies not only improve accuracy but also enable remote monitoring and data sharing, creating a seamless healthcare experience.

3. Shift Toward Self-Administration:
The increasing preference for at-home healthcare solutions has paved the way for patient-friendly injectable devices. Auto-injectors, pen injectors, and prefilled syringes are empowering patients to manage their health conditions with ease and confidence.

4. Growth of Biologics:
Biologic therapies are revolutionizing treatment for conditions like cancer, autoimmune disorders, and genetic diseases. Injectable systems are critical for the safe and effective delivery of these complex molecules, further boosting market demand.

Challenges and Opportunities:

While the injectable drug delivery market is poised for growth, it is not without its challenges. High development costs, stringent regulatory requirements, and the need for cold-chain logistics for biologics pose significant hurdles. However, these challenges present opportunities for innovation, particularly in developing cost-effective and sustainable solutions.

Emerging markets in Asia-Pacific, Latin America, and the Middle East offer untapped potential, driven by increasing healthcare investments, rising disposable incomes, and growing awareness of advanced medical technologies.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report! https://uk.finance.yahoo.com/news/injectable-drug-delivery-market-forecast-032500739.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACUVpPpPuSiFcnH8mIpnzAxHdz1umSb9lz1no-uaAJVsMXT2SILpDgnS-GGU88yV74-ZCBnIlNmyB77nqFN3WbthFNq4zMt4JUpFLbebwq6L2H7UhnKFiwmc87B94k-9OzgeLZn4We0tlWCmVnAdEkPnXPNjaFYHB5lA2f0Yph8c

Trends to Watch: The Next Big Innovations

1. Micro-Needle Patches:
Painless and efficient, micro-needle patches are gaining traction as an alternative to traditional injections. These patches can deliver drugs through the skin without causing discomfort, making them a promising innovation.

2. 3D Printing in Injectable Devices:
3D printing is opening doors to customized injectable devices tailored to individual patient needs, enhancing both efficacy and compliance.

3. Sustainable Materials:
With a growing focus on sustainability, manufacturers are exploring eco-friendly materials for injectable devices, reducing their environmental footprint.

Outlook for 2034: A Patient-Centric Era

As we look toward 2034, the injectable drug delivery market is expected to achieve remarkable advancements, reshaping patient care. The emphasis on personalized medicine, coupled with technological innovation, will define the next decade. This growth trajectory underscores the need for collaboration between pharmaceutical companies, technology providers, and healthcare systems to ensure access to safe, effective, and affordable injectable solutions.

The injectable drug delivery market from 2024 to 2034 is set to redefine how healthcare is delivered. With a focus on precision, convenience, and patient empowerment, the industry is charting a path toward a healthier future. By embracing innovation and addressing challenges, stakeholders can unlock the immense potential of this dynamic market.

Key Takeaways from the Market Study:

• The insulin pins segment dominates the injectable drug delivery market with an expected share of 50.50% in 2024.
• Based on the technology, the non-smart injectors segment leads the injectable drug delivery industry with an anticipated share of 83.80% in 2024.
• The injectable drug delivery industry in India is anticipated to grow at a CAGR of 9.50% through 2034.
• The injectable drug delivery industry in China is estimated to rise at a 10.10% CAGR through 2034.
• The injectable drug delivery industry in Brazil has the potential to increase at 9.80% CAGR through 2034.
• The United Kingdom injectable drug delivery industry is predicted to rise by 8.80% CAGR through 2034.
• The injectable drug delivery market in Japan is anticipated to grow at a CAGR of 8.50% through 2034.

“With the rising incidences of chronic diseases in developing and developed parts of the world, companies involved in the injectable drug delivery market must curate product offerings that cater to diverse patient needs, enhance treatment adherence, and ensure efficient and precise drug delivery”, opines an FMI analyst.

Competitive Landscape:

The injectable drug delivery market is constantly evolving, with innovations and methodologies entering the market regularly.

• International companies are investing billions of dollars in developing new devices and medical procedures for the healthcare sector, which is likely to result in an upward trend in the market.
• Domestic companies are developing devices according to their country's specific needs. For instance, Japan-based companies are developing products to address the healthcare needs of their aging population.

Recent Developments:

• February 2024 - Silo Pharma, Inc. successfully delivers SP-26 Ketamine Implant for fibromyalgia and chronic pain treatment.
• January 2024 - Kindeva Drug Delivery launches a new global business unit, offering analytical support for the pharmaceutical and medical device sector.

Key Companies:

• Becton Dickinson and Company
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Novo Nordisk A/S
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Johnson & Johnson
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• Baxter International Inc.
• Roche Holding AG

Key Segments of the Injectable Drug Delivery Industry:

By Product Type:

• Self-Injector
• Needle-Free Injectors
• Auto-Injectors
• Wearable Injectors
• Insulin Pens

By Technology:

• Non-Smart Injectors
• Smart Injectors

By Usage:

• Disposable Injectors
• Reusable Injectors

By Indication:

• Anaphylaxis
• Diabetes
• Cardiovascular Disease
• Multiple Sclerosis
• Rheumatoid Arthritis
• Cancer

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• Asia Pacific (APAC)
• Middle East & Africa (MEA)

Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:

As per the latest market research conducted by FMI, the global microneedle drug delivery systems market size is expected to record a CAGR of 6.6% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of USD 768.9 million. By 2033, the valuation is anticipated to reach USD 1459.1 million.

The injectable drug market share is evaluated to be sized at USD 5,97,980.6 million in 2024. During the period from 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 5.8%. By 2034, the injectable drug market is anticipated to have reached a value of USD 9,91,631.3 million.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
email us here
Visit us on social media:
Facebook
X
LinkedIn
YouTube